Amesite (AMST) investor relations material

Company overview and business model

• Focuses on AI-powered solutions for the healthcare sector, especially post-acute care, after pivoting from an education-centric model in fiscal 2025.

• Operates two product lines under the NurseMagic™ brand: a B2C app for nurses/caregivers and a B2B enterprise platform for healthcare organizations.

• B2C app reduces documentation time and supports workflow; B2B platform targets home health, skilled nursing, hospice, and non-clinical segments, emphasizing compliance and efficiency.

• Technology platform is built for rapid, secure deployment, with a focus on user-driven feature development and regulatory compliance.

• Holds 14 U.S. patents and has additional pending applications covering AI, security, and learning systems.

Financial performance and metrics

• Net losses of approximately $3.6 million in fiscal year ended June 30, 2025, and $4.4 million in 2024.

• Historical net tangible book value as of December 31, 2025, was $0.21 per share; post-offering, as adjusted net tangible book value would be $0.74 per share.

• Company has not yet established a stable, recurring revenue base sufficient to cover ongoing expenses.

• There is substantial doubt about the ability to continue as a going concern, with management planning to generate cash through financing transactions.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.47 million (or $5.16 million if over-allotment is exercised in full) at an offering price of $1.80 per share and warrant.

• Proceeds intended for working capital and general corporate purposes; management has broad discretion over allocation.

• Additional proceeds possible if warrants are exercised for cash, but timing and likelihood are uncertain.